tiprankstipranks
Trending News
More News >
SCYNEXIS (SCYX)
NASDAQ:SCYX

SCYNEXIS (SCYX) AI Stock Analysis

Compare
1,540 Followers

Top Page

SC

SCYNEXIS

(NASDAQ:SCYX)

Rating:40Underperform
Price Target:
$0.50
▼(-30.56%Downside)
SCYNEXIS is facing considerable challenges with negative financial performance and technical indicators. The potential Nasdaq delisting further exacerbates risk, overshadowing any valuation upside. Investors should be cautious given the high volatility and operational inefficiencies.
Positive Factors
Clinical Trials
The FDA clinical hold on the P3 MARIO study of Brexafemme has been lifted, allowing Synexis to resume the study.
Financial Stability
Scynexis has $53M in cash as of the end of 1Q25 which should provide runway into mid-2026, so the MARIO trial can continue.
Product Approval
Brexafemme, the first-in-class triterpenoid antifungal, has broad-spectrum fungicidal activity and is approved for vulvovaginal candidiasis.
Negative Factors
Legal Disputes
The dispute between GSK and Scynexis regarding MARIO study milestone payments of $30M continues.
Manufacturing Issues
Lowering the 12-month price target to $4.00, from $8.00, due to ongoing uncertainty with GSK on manufacturing issues related to Brexafemme commercialization.
Uncertain Revenue
Uncertainty around the timelines for Brexafemme commercial royalties and GSK's potential filing for approval in invasive fungal infections increases the revenue risk adjustment to 50%.

SCYNEXIS (SCYX) vs. SPDR S&P 500 ETF (SPY)

SCYNEXIS Business Overview & Revenue Model

Company DescriptionSCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
How the Company Makes MoneySCYNEXIS generates revenue through the commercialization of its antifungal treatments, particularly ibrexafungerp, which is marketed under the brand name BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC). The company earns money through product sales, licensing agreements, and strategic collaborations with other pharmaceutical companies. Revenue streams also include milestone payments and royalties associated with partnerships. SCYNEXIS's financial performance is significantly influenced by its ability to successfully market its product and expand global partnerships to broaden the reach of its antifungal therapies.

SCYNEXIS Financial Statement Overview

Summary
SCYNEXIS faces multiple financial challenges with declining revenue and profitability, a moderately leveraged balance sheet, and negative cash flow trends. The company needs to address its operational inefficiencies and improve its cash flow to enhance financial stability.
Income Statement
45
Neutral
SCYNEXIS shows significant volatility in its revenue and profitability. The revenue decreased sharply in 2024 from the previous year, and the company experienced a substantial net loss. The EBIT and EBITDA margins are negative, indicating operational challenges.
Balance Sheet
50
Neutral
The company's balance sheet reflects a moderate debt-to-equity ratio and relatively stable stockholders' equity. However, the equity ratio is low, suggesting a higher reliance on liabilities, which could be risky.
Cash Flow
40
Negative
The cash flow situation is concerning, with negative free cash flow and operating cash flow. The company has not been able to generate positive cash flow from its operations, indicating a potential liquidity issue.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.63M3.75M140.14M5.09M13.16M0.00
Gross Profit2.63M3.75M124.52M4.46M12.85M-303.00K
EBITDA-25.78M-18.58M73.48M-59.91M-31.41M-51.15M
Net Income-27.09M-21.29M67.04M-62.81M-32.87M-55.19M
Balance Sheet
Total Assets67.92M90.64M128.41M87.81M119.84M102.54M
Cash, Cash Equivalents and Short-Term Investments40.61M59.30M74.36M73.50M104.48M93.04M
Total Debt2.49M16.27M15.08M48.60M43.63M19.84M
Total Liabilities17.38M35.57M55.45M84.58M78.58M79.78M
Stockholders Equity50.53M55.08M72.96M3.23M41.26M22.76M
Cash Flow
Free Cash Flow-27.47M-24.01M60.16M-79.89M-55.73M-49.36M
Operating Cash Flow-27.47M-24.01M60.16M-79.88M-54.56M-49.35M
Investing Cash Flow13.14M6.15M-34.88M-27.39M-1.17M6.47M
Financing Cash Flow-14.21M-139.00K-36.72M48.60M67.12M94.00M

SCYNEXIS Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.72
Price Trends
50DMA
0.86
Negative
100DMA
0.93
Negative
200DMA
1.11
Negative
Market Momentum
MACD
-0.05
Positive
RSI
40.47
Neutral
STOCH
26.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.86, and below the 200-day MA of 1.11, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 40.47 is Neutral, neither overbought nor oversold. The STOCH value of 26.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCYX.

SCYNEXIS Risk Analysis

SCYNEXIS disclosed 45 risk factors in its most recent earnings report. SCYNEXIS reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

SCYNEXIS Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$27.96M-2.12%12.82%96.46%
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
45
Neutral
$20.69M-203.11%-41.45%40.69%
41
Neutral
$5.90M-59.14%-33.10%71.37%
40
Underperform
$28.10M-43.47%-98.13%-129.06%
31
Underperform
$32.58M-576.46%38.50%
$222.77M0.0857.63%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SCYX
SCYNEXIS
0.72
-1.15
-61.50%
CPHI
China Pharma Holdings
1.74
-0.86
-33.08%
DRRX
Durect
0.67
-0.64
-48.85%
RMTI
Rockwell Med
0.82
-0.90
-52.33%
KALA
Kala Pharmaceuticals
5.10
-1.80
-26.09%
SXTC
China SXT Pharmaceuticals
1.78
-6.54
-78.61%

SCYNEXIS Corporate Events

Executive/Board ChangesShareholder Meetings
SCYNEXIS Holds Annual Meeting, Re-elects Directors
Neutral
Jul 1, 2025

On June 25, 2025, SCYNEXIS, Inc. conducted its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and financial oversight. The meeting resulted in the re-election of seven directors, the ratification of Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2025, and the approval of executive compensation as outlined in the company’s proxy statement. These decisions are crucial for SCYNEXIS’s operational continuity and strategic planning, potentially impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (SCYX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.

Delistings and Listing ChangesRegulatory Filings and Compliance
SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price
Negative
Jun 26, 2025

On June 20, 2025, SCYNEXIS received a notification from Nasdaq regarding its failure to meet the minimum bid price requirement for its common stock, which has been below $1.00 for 30 consecutive business days. SCYNEXIS has until December 17, 2025, to regain compliance, with options including a reverse stock split if necessary. Failure to comply could result in delisting, although SCYNEXIS may appeal any delisting decision.

The most recent analyst rating on (SCYX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025